Teriparatide acetate - Generic Drug Details

What are the generic sources for teriparatide acetate and what is the scope of patent protection?

Teriparatide acetate is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for teriparatide acetate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Clinical Trials:	2
DailyMed Link:	teriparatide acetate at DailyMed

Recent Clinical Trials for teriparatide acetate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Asahi Kasei Pharma Corporation	Phase 1

See all teriparatide acetate clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for teriparatide acetate

H05AA	Parathyroid hormones and analogues
H05A	PARATHYROID HORMONES AND ANALOGUES
H05	CALCIUM HOMEOSTASIS
H	Systemic hormonal preparations, excluding sex hormones and insulins

US Patents and Regulatory Information for teriparatide acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	PARATHAR	teriparatide acetate	INJECTABLE;INJECTION	019498-001	Dec 23, 1987		DISCN	No	No

Teriparatide Acetate Market Dynamics, Patent Expiration, Generic Competition and Financial Trajectory

Last updated: August 31, 2026

Teriparatide acetate is the acetate salt of teriparatide, a recombinant parathyroid hormone analog used to stimulate bone formation in patients with severe osteoporosis and high fracture risk. The commercial market has shifted from Lilly’s branded Forteo franchise to lower-priced generic and follow-on teriparatide products. Core composition-of-matter protection has expired, FDA exclusivity has ended, and current value depends on manufacturing scale, device economics, payer access, physician familiarity and geographic execution.

The commercial outlook is mature rather than growth-driven. Revenue is declining for the originator but remains meaningful for generic manufacturers because teriparatide has a defined treatment role, limited duration of use and a large osteoporosis population.

What is teriparatide acetate and how is it used?

Teriparatide is a recombinant form of the biologically active 1-34 fragment of human parathyroid hormone. It is administered by subcutaneous injection, generally once daily. The drug is used for postmenopausal women and men with osteoporosis who have a high risk of fracture, including patients who have failed or cannot tolerate other osteoporosis treatments.

U.S. labeling historically limited lifetime exposure to 24 months. FDA removed the boxed warning concerning osteosarcoma risk in 2020 and revised the labeling to permit use beyond 24 months in patients who remain or return to having a high fracture risk, subject to individual clinical judgment.[1]

The commercial product is generally described as teriparatide injection rather than as a separate acetate product. “Teriparatide acetate” commonly identifies the active pharmaceutical ingredient or salt form in chemical and patent records. It does not represent a separate high-value branded market equivalent to Forteo.

What is the FDA regulatory status of teriparatide acetate?

The FDA approved Forteo in November 2002 under Eli Lilly’s new drug application.[2] Forteo was supplied as a multidose injection pen containing teriparatide. The FDA has since approved generic and follow-on versions of teriparatide injection.

Regulatory item	Status
Active ingredient	Teriparatide, recombinant PTH 1-34
Original U.S. brand	Forteo
Innovator	Eli Lilly
Initial FDA approval	2002
Administration	Subcutaneous injection
Primary indication	Severe osteoporosis and high fracture risk
NCE exclusivity	Expired
Pediatric exclusivity	Not a current commercial barrier
Generic pathway	Abbreviated New Drug Application and follow-on development
Biosimilar pathway	Generally not the principal U.S. pathway for Forteo because teriparatide is regulated as a drug product rather than as a separately licensed biologic reference product

The regulatory market now includes multiple teriparatide injection products. Device usability, delivery accuracy, storage, patient support and payer formulary placement are commercially important because the molecule itself is no longer strongly differentiated.

When did Forteo lose exclusivity?

Forteo lost meaningful regulatory and patent exclusivity years ago. The five-year new chemical entity exclusivity period associated with the original approval expired in 2007. The principal product and method patents also expired or became ineffective as barriers to generic entry during the following decade.

The main commercial turning point was the arrival of generic teriparatide products after the end of the original Forteo patent estate. Generic entry reduced the value of Lilly’s brand, although the decline was moderated by the complexity of peptide manufacturing and the need to supply a reliable injection device.

Teriparatide exclusivity timeline

Date	Event
2002	FDA approves Forteo
2007	Five-year NCE exclusivity expires
2017	Original core patent barriers are no longer effective as broad market protection
2019-2023	Generic and follow-on teriparatide products reach the U.S. market
2020	FDA removes Forteo’s boxed warning regarding osteosarcoma risk and revises duration language
2024 onward	Market is primarily exposed to generic price competition and differentiated anabolic osteoporosis products

The relevant commercial question is no longer when teriparatide acetate loses exclusivity. It has already entered the post-exclusivity phase. The question is which suppliers can maintain margin despite price erosion and manufacturing complexity.

What patents protect teriparatide acetate?

Teriparatide’s original protection covered the peptide, pharmaceutical compositions and therapeutic use. These patents were associated with Eli Lilly and its research predecessor organizations. Core protection has expired, leaving limited room for broad exclusion of competing teriparatide products.

Patent protection historically covered four main categories:

1. The recombinant teriparatide peptide and related biological production.
2. Pharmaceutical formulations and stabilizing excipients.
3. Injectable delivery systems and multidose pens.
4. Methods for treating osteoporosis and reducing fracture risk.

The expired core estate remains relevant in litigation and freedom-to-operate analysis because later patents can still affect a specific device, formulation or manufacturing process. Those later rights do not recreate the broad market exclusivity once provided by the composition and original therapeutic patents.

What formulations are protected by teriparatide patents?

Teriparatide formulations use an aqueous peptide solution that must maintain chemical stability and potency during storage and repeated use. Relevant formulation variables include pH, preservatives, stabilizers, adsorption control, container closure and compatibility with the injection pen.

Formulation patents can create narrower barriers than composition patents. A generic company may avoid infringement by using a different excipient system, concentration, container or delivery architecture. The practical value of a formulation patent depends on whether the formulation materially improves shelf life, manufacturing yield, device performance or patient adherence.

The highest-value intellectual property for current suppliers is therefore more likely to involve manufacturing and device execution than the teriparatide molecule itself.

What is the Orange Book status of Forteo?

Forteo’s historical Orange Book listings supported the originator’s patent certifications and litigation strategy. With the expiration of the principal listed patents, the Orange Book no longer provides Lilly with a broad barrier to teriparatide injection competition.

A current Orange Book review should distinguish between:

• Expired Forteo product patents.
• Any remaining or later-listed device or formulation claims.
• Patent certifications submitted by ANDA applicants.
• Litigation that could delay approval or launch.
• Patent rights outside the United States, where the protection timeline differs.

The commercial conclusion is clear: Orange Book-listed protection is not sufficient to preserve Forteo-level pricing. Generic applicants can rely on expired core protection and, where necessary, challenge narrower listed claims through Paragraph IV certifications.

Which companies are challenging the Forteo market?

The main competitive pressure comes from generic and follow-on teriparatide suppliers rather than from a single biosimilar challenger.

Relevant market participants have included:

• Eli Lilly, with Forteo.
• Teva Pharmaceuticals, with generic teriparatide injection.
• Alvogen and associated commercial partners.
• Pfenex, which developed a recombinant teriparatide product later commercialized through partner arrangements.
• Regional generic manufacturers in Europe, Asia and Latin America.
• Radius Health, with Tymlos, a competing anabolic osteoporosis product rather than a teriparatide generic.

Generic entry has focused on the active ingredient and injectable presentation. The principal competition is therefore between branded and generic teriparatide, not between multiple molecularly distinct versions of teriparatide acetate.

How strong is the teriparatide patent estate?

The estate is weak as a broad exclusivity platform and moderate in selected technical areas.

Patent area	Current strength	Commercial effect
Teriparatide composition	Low	Core protection expired
Broad osteoporosis method of use	Low	Generic entry is established
Formulation	Low to moderate	May affect specific products
Injection pen and delivery system	Moderate	Can raise development and substitution costs
Manufacturing process	Moderate	May protect know-how and improve economics
Trade secrets	Moderate to high	Relevant to peptide yield, purity and stability
Foreign patent rights	Country-specific	Can delay entry in selected markets

Manufacturing know-how can be more durable than patent protection. Teriparatide is a peptide, and suppliers must control aggregation, degradation, impurities, sterility and device filling. A product may be legally non-infringing but commercially unattractive if its yield, stability or device reliability is poor.

What generic entry risks exist for teriparatide acetate?

Generic entry has already changed pricing, but erosion is unlikely to be uniform across all channels.

U.S. risks

U.S. risks include:

• Multiple approved suppliers compressing wholesale acquisition cost.
• Formulary substitution away from Forteo.
• Reduced physician loyalty to the Lilly brand.
• Reimbursement pressure from Medicare and commercial plans.
• Pen-device costs that limit the number of economically viable competitors.
• Potential supply interruptions because peptide filling capacity is specialized.

A generic product that matches Forteo on device convenience and payer coverage can take share quickly. Products with weaker injection ergonomics may remain restricted to price-sensitive formularies.

European risks

European markets are more exposed to tendering, reference pricing and national reimbursement decisions. The timing of entry depends on country-specific patent rights, regulatory approval and local substitution rules. Price erosion can be sharper than in the United States, but market access is fragmented.

Emerging-market risks

Local manufacturers may compete aggressively on price, particularly where hospital procurement and out-of-pocket payment dominate. Regulatory standards, cold-chain requirements and quality consistency can limit the ability of low-cost suppliers to export broadly.

How does teriparatide compare with Tymlos and Evenity?

Teriparatide competes with abaloparatide, marketed as Tymlos by Radius Health, and romosozumab, marketed as Evenity by Amgen and UCB.

Product	Active ingredient	Mechanism	Administration	IP position	Market role
Forteo and generics	Teriparatide	PTH receptor agonist	Daily injection	Mature, largely expired	Established anabolic therapy
Tymlos	Abaloparatide	PTH1 receptor agonist	Daily injection	More recent branded estate	Differentiated anabolic alternative
Evenity	Romosozumab	Sclerostin inhibitor	Monthly injection	Active branded protection	Higher-convenience anabolic option
Prolia	Denosumab	RANKL inhibitor	Six-month injection	Branded biologic estate	Antiresorptive, not anabolic
Bisphosphonates	Multiple agents	Antiresorptive	Oral or intermittent injection	Mostly mature	Lower-cost first-line therapy

Teriparatide’s advantages are long clinical familiarity, broad physician awareness and generic pricing. Its disadvantages are daily injections, product complexity and competition from newer products with less frequent dosing.

Evenity has a stronger convenience proposition but carries cardiovascular safety considerations. Tymlos competes directly in the daily anabolic segment and can use commercial contracting and patient-support programs to defend share.

What is the financial trajectory for teriparatide acetate?

The financial trajectory has four phases:

1. Rapid branded growth after Forteo approval.
2. Peak or near-peak sales during the period of limited competition.
3. Decline after patent expiry and generic entry.
4. Mature, lower-margin volume supported by generic demand and continued osteoporosis prevalence.

Lilly reported Forteo sales at roughly the billion-dollar scale during its mature branded years, before subsequent erosion from competition and loss of exclusivity.[3] Forteo is no longer a major disclosed growth driver in Lilly’s portfolio. Lilly’s financial reporting increasingly groups or de-emphasizes products that have become immaterial relative to newer franchises.

Revenue drivers

The remaining market value is driven by:

• Number of high-risk osteoporosis patients.
• Duration of anabolic treatment.
• Generic price discounts.
• Formularies and Medicare coverage.
• Physician use after antiresorptive treatment failure.
• Availability of injection devices.
• Regional reimbursement.
• Manufacturing cost per cartridge or pen.

Margin outlook

Generic margins are likely to be higher than those of commodity small molecules when the supplier has:

• Reliable recombinant peptide production.
• Scaled sterile filling.
• An efficient pen or cartridge platform.
• Low rejection and degradation rates.
• Strong payer access.
• Limited direct competition in a particular region.

Margins fall rapidly when several suppliers achieve equivalent device and quality profiles. Branded margins remain higher per unit but face volume loss and payer substitution.

What licensing deals affect the teriparatide market?

The market has depended on partnerships involving peptide development, recombinant production, regulatory filings, pen devices and regional commercialization. Pfenex’s teriparatide program illustrated the role of platform technology and partner commercialization in a post-Forteo market.[4]

Licensing value is now concentrated in:

• Regional commercialization rights.
• Manufacturing technology.
• Device platforms.
• Formulation know-how.
• Supply agreements.
• Co-development of follow-on products.

A license to the molecule itself has limited strategic value because the core active ingredient is no longer protected. A license that secures low-cost, high-yield production or a differentiated delivery system can retain commercial value.

What patent litigation and Paragraph IV risks affect teriparatide?

The primary Paragraph IV risk arose when ANDA applicants challenged listed Forteo patents or asserted that the relevant patents were expired, invalid or not infringed. Once core patents expired, the ability of litigation to delay generic entry declined substantially.

Current litigation risk is more likely to concern:

• Device patents.
• Formulation patents.
• Manufacturing patents.
• Labeling or method-of-use claims.
• Contract disputes between suppliers and commercial partners.

For investors and licensors, a standard patent-count approach overstates the strength of the estate. The key analysis is claim scope, remaining term, enforceability, design-around potential and whether the claim covers the commercially necessary presentation.

What is the generic launch scenario for teriparatide acetate?

The most likely commercial scenario is continued multi-supplier competition with a declining branded share.

Scenario	Market outcome	Financial implication
One or two reliable generics	Moderate price erosion	Generic suppliers retain attractive margins
Three or more equivalent generics	Heavy price erosion	Volume grows but unit economics weaken
Device differentiation	Slower substitution	Premium pricing may persist
Supply disruption	Temporary price recovery	Alternative suppliers gain share
Strong uptake of Evenity or Tymlos	Lower teriparatide volume	Anabolic segment remains competitive
Expanded use beyond 24 months	Higher treated volume	Supports demand, subject to reimbursement

The base case is stable or modestly declining total revenue, with continued unit demand but lower average selling prices. A material rebound would require broader treatment eligibility, better reimbursement, supply constraints affecting competitors or a differentiated delivery product.

What is the revenue exposure for pharmaceutical companies?

Lilly has the greatest historical exposure because Forteo established the category and generated substantial mature-product revenue. Its current exposure is limited compared with newer Lilly products.

Generic companies have lower revenue per product but can achieve attractive returns if they control manufacturing and secure formulary access. Radius Health has strategic exposure through Tymlos, which competes for the same high-risk osteoporosis patients but does not depend on teriparatide pricing.

For manufacturers, the main risk is not molecule discovery. It is the conversion of technical capability into a reliable, reimbursed and commercially supported injection product.

What geographic coverage does teriparatide have?

Teriparatide is marketed across the United States, Europe and several Asian and Latin American markets. Coverage varies by:

• Patent expiry date.
• National reimbursement policy.
• Local generic substitution.
• Regulatory classification.
• Availability of recombinant peptide manufacturing.
• Procurement and tender structures.

The United States offers the largest commercial opportunity per patient but has high payer and device-management pressure. Europe offers broad patient access but greater price control. Japan and other Asian markets can provide growth through aging demographics, although local approval and reimbursement requirements affect launch timing.

Key Takeaways

• Teriparatide acetate is the active peptide form associated with teriparatide injection; it is not a separate protected innovator franchise.
• Forteo’s core exclusivity has expired, and generic entry is established.
• The market is shifting from branded pricing to generic volume and manufacturing efficiency.
• Formulation, injection-pen and manufacturing patents have more practical relevance than expired composition patents.
• Lilly’s Forteo revenue trajectory is mature and declining, while generic suppliers compete on cost, quality and payer access.
• Tymlos and Evenity are the principal branded competitors in the anabolic osteoporosis segment.
• The strongest commercial barriers are peptide manufacturing, sterile filling, device reliability and reimbursement execution.
• Total market demand remains supported by osteoporosis prevalence, but average selling prices are under pressure.

FAQs

Is teriparatide acetate the same as Forteo?

Yes. Forteo contains teriparatide. “Teriparatide acetate” generally refers to the acetate salt or active pharmaceutical ingredient description rather than a separate branded medicine.

Can a generic manufacturer launch teriparatide without a license from Lilly?

Yes. A manufacturer can rely on the ANDA pathway after applicable patents and exclusivities expire or can challenge listed patents through Paragraph IV certification.

Does teriparatide have biosimilar competition?

In the United States, teriparatide competition is generally structured through generic or follow-on drug pathways rather than the conventional biosimilar pathway used for licensed biologics.

Which osteoporosis drug has the strongest current commercial differentiation?

Evenity has a strong dosing-convenience advantage because it is administered monthly, while Tymlos and teriparatide are daily injections. Clinical safety, reimbursement and treatment sequencing limit direct commercial comparability.

Is teriparatide still commercially attractive for generic manufacturers?

Yes, but primarily for suppliers with efficient peptide production, reliable sterile filling, a competitive delivery device and strong formulary access. The molecule alone provides limited pricing power.

References

1. U.S. Food and Drug Administration. (2020). FDA approves new labeling for Forteo to remove boxed warning about potential risk of osteosarcoma. FDA Drug Safety Communication.

2. U.S. Food and Drug Administration. (2002). Forteo approval letter and prescribing information. Center for Drug Evaluation and Research.

3. Eli Lilly and Company. (2018). Annual report 2018. Indianapolis, IN: Author.

4. Pfenex Inc. (2019). Pfenex announces FDA approval of teriparatide injection. Company press release.

5. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

6. U.S. Food and Drug Administration. (2024). Drugs@FDA: Forteo and teriparatide injection product information. Center for Drug Evaluation and Research.